Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025

Innocan Pharma granted first patent in India for its Liposomal CBD Injection

Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market

Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025

This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab

FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL

Approval is based on positive data from the Phase 3 ECHELON-3 trial

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo

Pharmexcil appoints Bhavin Mukund Mehta as Vice Chairman

Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin